KEYTRUDA® (pembrolizumab): Superior Survival vs Platinum-Containing Chemotherapy in Metastatic NSCLC KEYTRUDA® (pembrolizumab): Superior Survival vs Platinum-Containing Chemotherapy in Metastatic NSCLC

Keytruda:

Superior
Survival vs platinum-containing chemotherapy

Only anti–PD-1 approved for
first-line treatment
of mNSCLC with
high PD-L1 expression (TPS ≥50%)

  • 40% reduction in the risk of death vs chemotherapy in mNSCLC with high PD-L1 expression (TPS ≥50%) (hazard ratio [HR]=0.60; 95% confidence interval [CI], 0.41–0.89; P=0.005).a
  • 50% reduction in the risk of progression or death vs chemotherapy in mNSCLC with high PD-L1 expression (TPS ≥50%) (HR=0.50; 95% CI, 0.37–0.68; P<0.001).

aP-value is compared with 0.0118 of the allocated alpha for this interim analysis.

PD-1 = programmed death receptor-1; mNSCLC = metastatic NSCLC;
PD-L1 = programmed death ligand 1; TPS = tumor proportion score.